Patents by Inventor Suad Efendic

Suad Efendic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Somatostatin receptor antagonists and glucose control or hypoglycemia
    Patent number: 8206722
    Abstract: The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: June 26, 2012
    Assignee: The Governing Council of the University of Toronto
    Inventors: Mladen Vranic, Jessica Yue, Suad Efendic
  • Somatostatin Receptor Antagonists and Glucose Control or Hypoglycemia
    Publication number: 20110064742
    Abstract: The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 17, 2011
    Inventors: Mladen Vranic, Jessica Yue, Suad Efendic
  • Method of controlling tight blood glucose by somatostatin receptor antagonists
    Patent number: 7862825
    Abstract: The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: January 4, 2011
    Inventors: Mladen Vranic, Jessica Yue, Suad Efendic
  • SOMATOSTATIN RECEPTOR ANTAGONISTS AND GLUCOSE CONTROL OR HYPOGLYCEMIA
    Publication number: 20090004195
    Abstract: The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor.
    Type: Application
    Filed: February 21, 2008
    Publication date: January 1, 2009
    Inventors: Mladen Vranic, Jessica Yue, Suad Efendic
  • Methods for identifying compounds for treating diabetes mellitus
    Patent number: 7381523
    Abstract: The invention is directed to methods for identifying candidate beta cell-sensitizing compounds comprising providing a pancreatic beta islet cell population derived from a diabetic subject, contacting the beta islet cell population with one or more somatostatin receptor 5-binding compounds, and identifying those somatostatin receptor 5-binding compounds that promote insulin secretion from the pancreatic beta islet cell population at a higher rate than from a control cell population. The invention is further directed to methods for treating type II diabetes comprising administering a beta cell-sensitizing compound identified by the first method of the invention to a diabetic patient in need of treatment.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: June 3, 2008
    Assignee: BioCrine AB
    Inventor: Suad Efendic
  • Method of reducing mortality and morbidity associated with critical illnesses
    Publication number: 20080032932
    Abstract: This invention relates to the use of glucagon-like peptide (GLP-1) compound to reduce the mortality and morbidity associated with critical illnesses wherein a patient is predisposed to or suffers from some type of respiratory distress.
    Type: Application
    Filed: August 22, 2007
    Publication date: February 7, 2008
    Inventors: Joseph Jakubowski, Suad Efendic
  • USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION
    Publication number: 20080009433
    Abstract: This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
    Type: Application
    Filed: December 21, 2006
    Publication date: January 10, 2008
    Inventor: Suad Efendic
  • Use of a peptide
    Publication number: 20070225212
    Abstract: The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.
    Type: Application
    Filed: March 19, 2007
    Publication date: September 27, 2007
    Inventors: Suad Efendic, Mark Gutniak, Ole Kirk
  • USE OF GLP-1 ANALOGS AND DERIVATIVES ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY
    Publication number: 20070173452
    Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
    Type: Application
    Filed: March 30, 2007
    Publication date: July 26, 2007
    Inventors: Richard DiMarchi, Suad Efendic
  • Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
    Patent number: 7211557
    Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: May 1, 2007
    Assignee: Eli Lilly and Company
    Inventors: Richard DiMarchi, Suad Efendic
  • Methods for identifying compounds for treating diabetes mellitus
    Publication number: 20070003986
    Abstract: The invention is directed to methods for identifying candidate beta cell-sensitizing compounds comprising providing a pancreatic beta islet cell population derived from a diabetic subject, contacting the beta islet cell population with one or more somatostatin receptor 5-binding compounds, and identifying those somatostatin receptor 5-binding compounds that promote insulin secretion from the pancreatic beta islet cell population at a higher rate than from a control cell population. The invention is further directed to methods for treating type II diabetes comprising administering a beta cell-sensitizing compound identified by the first method of the invention to a diabetic patient in need of treatment.
    Type: Application
    Filed: August 25, 2006
    Publication date: January 4, 2007
    Inventor: Suad Efendic
  • Use of a peptide
    Publication number: 20060247174
    Abstract: The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.
    Type: Application
    Filed: July 13, 2006
    Publication date: November 2, 2006
    Inventors: Suad Efendic, Mark Gutniak, Ole Kirk
  • Use of GLP-1 or analogs in treatment of stroke
    Publication number: 20060160740
    Abstract: This invention provides a method of reducing mortality and morbidity associated with stroke. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
    Type: Application
    Filed: March 7, 2006
    Publication date: July 20, 2006
    Inventor: Suad Efendic
  • Methods for identifying compounds for treating diabetes mellitus
    Publication number: 20050287557
    Abstract: The invention is directed to methods for identifying candidate beta cell-sensitizing compounds comprising providing a pancreatic beta islet cell population derived from a diabetic subject, contacting the beta islet cell population with one or more somatostatin receptor 5-binding compounds, and identifying those somatostatin receptor 5-binding compounds that promote insulin secretion from the pancreatic beta islet cell population at a higher rate than from a control cell population. The invention is further directed to methods for treating type II diabetes comprising administering a beta cell-sensitizing compound identified by the first method of the invention to a diabetic patient in need of treatment.
    Type: Application
    Filed: May 6, 2005
    Publication date: December 29, 2005
    Inventor: Suad Efendic
  • Glucagon-like peptides (glp-1) and treatment of respiratory distress
    Publication number: 20040235726
    Abstract: This invention relates to the use of glucagon-like peptide (GLP-1) compounds to reduce the mortality and morbidity associated with critical illnesses wherein a patient is predisposed to or suffers from some type of respiratory distress.
    Type: Application
    Filed: March 4, 2004
    Publication date: November 25, 2004
    Inventors: Joseph Anthony Jakubowski, Suad Efendic
  • Use of GLP-1 or analogs in treatment of myocardial infarction
    Publication number: 20040162241
    Abstract: This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
    Type: Application
    Filed: March 29, 2004
    Publication date: August 19, 2004
    Inventor: Suad Efendic
  • Use of GLP-1 or analogs in treatment of myocardial infarction
    Patent number: 6747006
    Abstract: This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: June 8, 2004
    Assignee: Eli Lilly and Company
    Inventor: Suad Efendic
  • Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
    Publication number: 20040018975
    Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
    Type: Application
    Filed: May 5, 2003
    Publication date: January 29, 2004
    Inventors: Richard DiMarchi, Suad Efendic
  • Use of GLP-1 analogs and derivative adminstered peripherally in regulation of obesity
    Patent number: 6583111
    Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: June 24, 2003
    Assignee: Eli Lilly and Company
    Inventors: Richard DiMarchi, Suad Efendic
  • Use of a peptide
    Publication number: 20030083259
    Abstract: The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.
    Type: Application
    Filed: August 22, 2002
    Publication date: May 1, 2003
    Inventors: Suad Efendic, Mark Gutniak, Ole Kirk